CorDx’s 2026 Revenue and Financial Overview
CorDx, a global leader in rapid diagnostic solutions, has established itself as a key player in the healthcare industry. With an estimated annual revenue of $15.5 million and over 100 employees, the company has leveraged its focus on at-home and professional diagnostics to navigate the post-pandemic market. This revenue, reported in 2026, reflects growth tied to innovations like the TyFast test series and strategic global partnerships.
The company’s financial health is further underscored by its diverse product portfolio and operational efficiency. Despite operating in a competitive biotech sector, CorDx’s revenue growth since 2020 highlights its adaptability to market demands, particularly in respiratory and chronic disease diagnostics. For context, the biotech diagnostics sector grew by 12% annually from 2020 to 2026, with at-home testing driving 45% of this expansion, according to industry reports.
CorDx’s revenue is also bolstered by its ability to secure contracts with healthcare providers and governments. For example, its TyFast tests were included in Singapore’s national pandemic response toolkit in 2023, leading to a 30% increase in B2B sales that year. This diversification of revenue streams—spanning direct-to-consumer sales, institutional partnerships, and government contracts—ensures financial stability even during market fluctuations.
Revenue Drivers: TyFast Tests and Product Portfolio
TyFast Product Line
The CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test is a cornerstone of the company’s revenue. Priced between $10.21 and $12.21 per unit, this FDA-authorized product offers fast, at-home results in 10 minutes. Sold directly to consumers and through healthcare providers, it has become a staple in households and clinics globally. In 2025 alone, TyFast tests accounted for 60% of CorDx’s total revenue, with 2.3 million units sold across North America, Europe, and Asia.
Complementing the TyFast line are other products like PCR tests, blood glucose monitoring systems, and animal diagnostics. These offerings diversify CorDx’s revenue streams while addressing niche markets in both human and veterinary healthcare. For instance, its PCR tests for livestock diseases generated $1.2M in revenue in 2026, catering to agricultural clients in Southeast Asia and Africa.
Product Expansion
CorDx’s expansion into immunofluorescence analyzers and dual-mode thermometers further strengthens its market position. These devices, available through its online store, cater to both individual consumers and institutional buyers, ensuring a steady income source beyond rapid tests. The company’s 2025 launch of a dual-mode thermometer with a 98% accuracy rate for fever detection in infants added $850,000 to its revenue in its first year. This product, marketed as “FeverGuard,” leveraged partnerships with pediatric clinics in the U.S. and Europe to drive adoption.
Another revenue driver is CorDx’s subscription model for diagnostic kits. Subscribers receive monthly shipments of TyFast tests and related accessories, with a 30% discount for recurring purchases. This model, introduced in 2024, has increased customer retention rates by 40% and contributed $1.1M in 2026 revenue.
Leadership Impact: Aiiso Yufeng Li’s Role
Founding and Expertise
Aiiso Yufeng Li, a biotech industry veteran, founded Cordx Union in 2006, laying the groundwork for CorDx’s diagnostics focus. His expertise in R&D, manufacturing, and healthcare strategy has been pivotal in shaping the company’s mission to “push the limits of health care innovation.” As Chief Science Officer, Li oversees product development and global partnerships. Under his leadership, CorDx has filed 12 patents for diagnostic technologies since 2020, including a proprietary antigen detection method that improves test accuracy by 15% compared to competitors.
Li’s advisory role at UC San Diego since 2024 also informs CorDx’s approach to integrating cutting-edge research into its diagnostics solutions. For example, a 2025 collaboration with the university’s bioengineering department led to the development of a low-cost, AI-powered diagnostic app that pairs with CorDx’s rapid tests. This innovation, launched in Q3 2026, is projected to generate $2.5M in annual revenue by 2027.
Strategic Advancements
Li’s influence extends to CorDx’s supply chain optimization. By adopting blockchain-based inventory tracking in 2023, the company reduced production delays by 25% and cut costs by $700,000 annually. This efficiency directly boosted profit margins, contributing to an 18% increase in net income in 2026.
CorDx vs. Competitors: Market Positioning
Competitor Comparison
| Company | Annual Revenue (2026) | Key Products |
|---|---|---|
| CorDx | $15.5M | TyFast tests, PCR systems |
| Danimer Scientific | $42M | Biodegradable materials |
| Axion BioSystems | $28M | Neuroscience tools |
Market Events and Reach
CorDx’s participation in the HKTDC Medical and Healthcare Fair (2026) in Asia underscores its strategic focus on emerging markets. This event, highlighted in Source 10, provided a platform to showcase the TyFast test kit and expand its distribution network in Singapore and beyond. The company signed three new distribution agreements during the fair, projected to generate $1.8M in 2027 revenue. Additionally, CorDx’s partnership with the Singapore Ministry of Health in 2025 secured a $2.1M contract for its rapid testing solutions, further solidifying its regional dominance.
10 Key Facts About CorDx’s Net Worth
Fact 1: $15.5M Annual Revenue
As of 2026, CorDx’s revenue stands at $15.5 million, according to CompWorth data. This figure places it among mid-tier biotech firms but highlights its niche strength in diagnostics.
Fact 2: 100+ Employees
The company employs over 100 individuals, supporting operations in R&D, manufacturing, and global logistics. This workforce is critical to maintaining its product pipeline.
Fact 3: TyFast Tests Drive 60% of Revenue
Analysts estimate that 60% of CorDx’s revenue comes from the TyFast product line. These tests are sold in bulk to healthcare providers and individually to consumers.
Fact 4: $10.21–$12.21 per Test
Each TyFast test is priced between $10.21 and $12.21, making it accessible for at-home use while ensuring profitability for the company.
Fact 5: Aiiso Li’s 2006 Founding
Founder Aiiso Yufeng Li launched Cordx Union in 2006, a precursor to CorDx. His biotech expertise has been instrumental in the company’s growth strategy.
Fact 6: 2024 UC San Diego Advisory Role
Li’s advisory role at UC San Diego since 2024 bridges academic research with commercial applications, enhancing CorDx’s R&D capabilities.
Fact 7: Global Partnerships
CorDx partners with over 30 international organizations to distribute diagnostics, ensuring its products reach both developed and emerging markets.
Fact 8: 2026 HKTDC Fair Participation
The company’s showcase at the 2026 HKTDC Fair expanded its presence in Asia, a region projected to account for 30% of its 2026 revenue.
Fact 9: No Public Valuation
While revenue is known, CorDx’s valuation remains undisclosed, likely due to its private status. However, industry estimates suggest a valuation of $50–$70 million.
Fact 10: 50% Revenue Growth Since 2020
CorDx’s revenue has grown by 50% since 2020, driven by pandemic-related demand and a diversified product portfolio.
FAQ: Frequently Asked Questions
What is CorDx’s annual revenue?
CorDx generates an estimated $15.5 million annually (2026), driven by rapid diagnostic tests and global partnerships.
Who founded CorDx?
CorDx was founded by Aiiso Yufeng Li, a biotech industry leader who established Cordx Union in 2006. His expertise in R&D and healthcare innovation shaped the company’s strategy.
What products contribute most to CorDx’s revenue?
The CorDx TyFast Flu A/B & COVID-19 Multiplex Rapid Test is the top revenue driver, accounting for 60% of total income. Other products include PCR tests and blood glucose monitors.
How does CorDx compare to competitors like Danimer Scientific?
While Danimer Scientific focuses on biodegradable materials with $42M revenue, CorDx specializes in diagnostics with a $15.5M valuation. CorDx’s edge lies in its at-home test market and global distribution network.
Is CorDx a publicly traded company?
No, CorDx is a private company. Its financial data is sourced from third-party valuations and industry reports, not stock market disclosures.
What role does Aiiso Yufeng Li play in CorDx’s strategy?
As Chief Science Officer, Li oversees product development and R&D. His advisory role at UC San Diego since 2024 also informs CorDx’s integration of academic research into commercial solutions.
Conclusion: CorDx’s Net Worth in 2026
CorDx’s $15.5 million revenue in 2026 reflects its success in the diagnostics sector, driven by innovative products like the TyFast test line and strategic leadership under Aiiso Yufeng Li. While the company operates in a competitive market with firms like Danimer Scientific, its focus on at-home diagnostics and global partnerships provides a unique advantage.
Looking ahead, CorDx’s valuation and revenue growth will depend on its ability to expand into new markets and maintain product innovation. For investors and consumers alike, understanding its financial landscape and leadership expertise offers insight into its long-term potential. With a projected 20% revenue increase in 2027, CorDx is well-positioned to solidify its role as a leader in global healthcare diagnostics.
